Richard Ratei

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Anja Möricke, Alfred Reiter, Martin Zimmermann et al. · Blood · 2008 · 610 citations · Full text

Medicine, Oncology, Pediatrics +14

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Martin Schrappe, Maria Grazia Valsecchi, Claus R. Bartram et al. · Blood · 2011 · 438 citations · Full text

Life Sciences, Immunology, Immunotherapy +3

Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90

Gesche Tallen, Richard Ratei, Georg Mann et al. · Journal of Clinical Oncology · 2010 · 315 citations

Medicine, Oncology, Chemotherapy +16

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

Giuseppe Basso, Marinella Veltroni, Maria Grazia Valsecchi et al. · Journal of Clinical Oncology · 2009 · 288 citations

Medicine, Hematology, Oncology +17

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Anja Möricke, Martin Zimmermann, Maria Grazia Valsecchi et al. · Blood · 2016 · 285 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +7